...
首页> 外文期刊>International Journal of Clinical and Experimental Pathology >A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer
【24h】

A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer

机译:基于三个基因的风险评分可预测切除的非小细胞肺癌的预后

获取原文

摘要

Background: To study the prognosis-predicting value of a risk score based on phosphorylated At (p-Akt), vascular endothelial growth factor (VEGF), and Nin one binding (NOB1) expression in patients with resected non-small-cell lung cancer (NSCLC). Methods: A prospective cohort among 98 consecutive patients with resected NSCLC was conducted in 2009 to 2010. Immunohistochemistry was used in the detection of p-Akt, VEGF, and NOB1 expression. Any of three genes with positive expression was allocated a score of 1, otherwise scored 0. The risk score ranged from 0-3. Prognosis outcomes included overall survival (OS) and progression-free survival (PFS). Log-rank test and Cox hazard model were used to investigate the prognosis predicting value for the risk score. Results: In the 98 NSCLC tissue specimens, p-Akt, VEGF and NOB1 positive Expression rates were 42.9%, 66.3%, and 60.2%, respectively. The median for OS was 44 month, with 95% CI 35-51 months, and the median for PFS was 36 months, with 95% CI 25-49 months. Log-rank test showed OS and PFS related with TMN stage, lymph node metastasis, p-Akt expression, VEGF expression, NOB1 expression, and gene-based risk score (P<0.05). Multivariate COX analysis showed pTMN stage, lymph node metastasis, p-Akt expression, VEGF expression, and gene-based risk score were independent prognosis factors for OS and PFS. The adjusted HR for gene-based risk score with every one score increase was 1.21 [1.04-1.56] for OS and 1.19 [1.02-1.79] for PFS. Conclusions: Our results suggest the risk scores based on p-Akt, VEGF, NOB1 expression can predict postoperative survival in patients with resected NSCLC.
机译:背景:基于切除的非小细胞肺癌患者,基于磷酸化At(p-Akt),血管内皮生长因子(VEGF)和Nin 1结合(NOB1)表达的风险评分的预后预测价值研究(NSCLC)。方法:对2009年至2010年连续切除的98例NSCLC患者进行前瞻性队列研究。采用免疫组织化学方法检测p-Akt,VEGF和NOB1的表达。阳性表达的三个基因中的任何一个的得分为1,否则为0。风险得分为0-3。预后结果包括总体生存期(OS)和无进展生存期(PFS)。采用log-rank检验和Cox风险模型研究风险评分的预后预测值。结果:在98例NSCLC组织样本中,p-Akt,VEGF和NOB1阳性表达率分别为42.9%,66.3%和60.2%。 OS的中位数为44个月,CI值为35-51个月,为95%,PFS的中位数为36个月,CI值为25-49个月,为95%。 Log-rank检验显示OS和PFS与TMN分期,淋巴结转移,p-Akt表达,VEGF表达,NOB1表达和基于基因的危险评分有关(P <0.05)。多变量COX分析显示pTMN分期,淋巴结转移,p-Akt表达,VEGF表达和基于基因的危险评分是OS和PFS的独立预后因素。基于基因的风险评分的校正后HR,OS升高1.21 [1.04-1.56],PFS升高1.19 [1.02-1.79]。结论:我们的结果表明,基于p-Akt,VEGF,NOB1表达的风险评分可以预测NSCLC切除术后患者的生存情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号